Category: Research
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Dr. Ou at ALKtALK
Dr. Ignatius Sai-Hong Ou – Professor in Hematology-Oncology, Medical Oncology University of California, Irvine Editor-in-Chief of Lung Cancer: Targets and Therapy Associate Editor of Journal of Thoracic Oncology Question: We want to know a little about you. What brought you to study ALK? I was just a young aimless attending (MD) in 2007. I was…
-
International Ambassadors Survey- ALK Life Study
An informal survey was conducted with our ALK International Ambassadors, volunteers from various countries who are passionate about sharing their experiences with others. A total of 22 countries were represented in this survey. In addition to the US, European nations were well represented, as were Australia and New Zealand. There was a notable lack of…
-
Gilteritinib overcomes Lorlatinib resistance in ALK-rearranged cancer
by Mizuta et al. (Japan) A common problem we face is that cancer becomes resistant to our TKIs (Crizotinib, Brigatinib, Alectinib, Ceritinib, and Lorlatinib) over time. There are two known mechanisms so far for resistance. One is for the cancer cells to activate an alternative bypass pathway such as EGFR, cMET, KRAS, or AXL to…
-
So what about immunotherapy?
The hot phrase in cancer treatment is immunotherapy right now. What does it mean for ALK+patients? Sometimes, you hear that immunotherapy does not work? But why are we trying to fund and are funding vaccines? Don’t vaccines work with the immune system? This short summary is to clarify these questions for you. There is an…
-
Dr. Vincent Lam at ALKtALK
Director, Esophageal Cancer Research Program, Assistant Professor of Oncology Expertise: Esophageal Cancer & Lung cancer Dr Lam: I am so excited to join your conversation tonight on a Sunday evening. I’m scrolling through five pages of people on the zoom call. It’s just amazing to see how committed and engaged you all are. That’s a…
-
Dr. Benjamin Levy & NPC Rasheda Persinger join ALKtALK
BENJAMIN PHILLIP LEVY, MD, Clinical Director of Medical Oncology Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Associate Professor of Oncology RASHEDA PERSINGER, Nurse Practitioner Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Deborah Kimmel, a patient since January 2018, gave an introduction. “Dr. Levy is one of the leading Thoracic…
-
ALK Genetics 101
About two years ago (before Dr. Ken Culver was hired as ALK Positive Inc Director of Research and Clinical Affairs, and Colin Barton was still leading the ALK Positive Inc Medical Committee), Colin received an email from Dr. Justin Gainor and Dr. Jessica Lin from Massachusetts General Hospital, inviting ALK Positive Inc to contribute to…
-
Real World Data in Medical Research
What is real world data vs. on-paper data? Scientists create experiments in laboratories and present the best data they can in published papers for everyone to share. That’s paper data. In real life, clinical doctors prescribe the medication and the end results for people are the real-world data. Most of the time, this section highlights…
-
Dr. Justin Gainor & Dr. Aaron Hata join ALKtALK
Dr. Justin Gainor, MD Director of Center for Thoracic Cancers & Director of Targeted Immunotherapy at Massachusetts General Hospital, Boston Assistant Professor of Medicine at Harvard Medical School “It’s great to be here tonight. It’s so nice to see so many familiar faces on the call. Being one of the recipients for the ALK Positive…
-
Dr. Mark Awad & Dr. Roberto Chiarle join ALKtALK
Mark Awad, MD, PhD Clinical Director, Thoracic Oncology Treatment Center Assistant Professor of Medicine, Harvard Medical School I hope everyone is safe, warm, and healthy tonight. I am the Clinical Director of Thoracic Oncology at Dana Farber Cancer Institute in Boston, MA. I did Medical School at John’s Hopkins, medical residency at Mass General, and…
-
Ensartinib: the unknown TKI
Ensartinib (x396) is a medicine made by Xcovery, a biotech company based in Florida. It works closely with another company called Betta Pharmaceuticals in China for many of its trials. Currently, there is an eXalt3 (phase 3) clinical trial to compare Ensartinib against Xalkori (not currently recruiting). Originally, there was a phase1/2 trial done in…